Moderna (XSWX:MRNA) Stock Based Compensation: CHF377 Mil (TTM As of Mar. 2026)


XSWX:MRNA Moderna Inc XSWX:MRNA
62 GF Score
Price CHF57.81
GF Value CHF18.28
! 7 Warning Signs
View Full Analysis

What is Moderna Stock Based Compensation?

Moderna XSWX:MRNA 62 Stock Based Compensation is CHF377 Mil as of Mar. 2026. GuruFocus rates XSWX:MRNA with a GF Score™ of 62/100 and a GF Value™ of CHF18.28. The stock has 7 warning signs investors should review.

Moderna's Stock Based Compensation for the three months ended in Mar. 2026 was CHF82 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was CHF377 Mil.

Moderna Stock Based Compensation Related Terms

Moderna Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Moderna's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moderna Stock Based Compensation Chart

Moderna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 130.78 210.54 263.76 382.50 384.90

Moderna Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 101.61 105.72 99.51 90.05 81.88
XSWX:MRNA
62GF Score
Moderna Inc XSWX:MRNA
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moderna Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF377 Mil.

What does a Stock Based Compensation of CHF377 Mil mean?
Moderna (XSWX:MRNA) has a Stock Based Compensation of CHF377 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Moderna and its competitors.
Is Moderna's Stock Based Compensation too high?
Moderna's current Stock Based Compensation is CHF377 Mil. Overall, Moderna has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Moderna's Stock Based Compensation compare to RPRX and ROIV?
Moderna's Stock Based Compensation of CHF377 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Moderna and its competitors. Moderna's current Stock Based Compensation is CHF377 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moderna stock overvalued right now?
Moderna (XSWX:MRNA) has a current Stock Based Compensation of CHF377 Mil. The stock's GF Value™ is CHF18.28, compared to a current price of CHF57.81 — trading 216.2% above its estimated fair value. The current Stock Based Compensation is CHF377 Mil. Moderna's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Moderna (XSWX:MRNA), the current Stock Based Compensation is CHF377 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moderna (XSWX:MRNA) Overvalued in 2026?

Based on GuruFocus' analysis, Moderna stock appears to be overvalued. The current stock price of CHF57.81 is trading 216.2% above its estimated GF Value™ of CHF18.28.

Key valuation signals for XSWX:MRNA:

  • Stock Based Compensation: CHF377 Mil
  • GF Value™: CHF18.28 vs. price of CHF57.81 (216.2% above fair value)
  • GF Score™: 62/100 with 7 warning signs

No single metric tells the full story. See the XSWX:MRNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moderna Business Description

Address 325 Binney Street, Cambridge, MA, USA, 02142
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
62GF Score

Get the complete analysis for XSWX:MRNA

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF57.81
Price
CHF18.28
GF Value